ROS1型
医学
肿瘤科
内科学
队列
危险系数
腺癌
肺癌
克拉斯
精密医学
癌症
置信区间
病理
结直肠癌
作者
Ronglai Shen,Axel Martin,Ai Ni,Matthew D. Hellmann,Kathryn C. Arbour,Emmet Jordan,Arshi Arora,Ryan Ptashkin,Ahmet Zehir,Mark G. Kris,Charles M. Rudin,Michael F. Berger,David B. Solit,Venkatraman Seshan,Maria E. Arcila,Marc Ladanyi,Gregory J. Riely
摘要
PURPOSE Broad-panel sequencing of tumors facilitates routine care of people with cancer as well as clinical trial matching for novel genome-directed therapies. We sought to extend the use of broad-panel sequencing results to survival stratification and clinical outcome prediction. METHODS By using sequencing results from a cohort of 1,054 patients with advanced lung adenocarcinomas, we developed OncoCast, a machine learning tool for survival risk stratification and biomarker identification. RESULTS With OncoCast, we stratified this patient cohort into four risk groups on the basis of tumor genomic profile. Patients whose tumors harbored a high-risk profile had a median survival of 7.3 months (95% CI, 5.5 to 10.9 months) compared with a low-risk group with a median survival of 32.8 months (95% CI, 26.3 to 38.5 months) with a hazard ratio of 4.6 ( P < .001), far superior to any individual gene predictor or standard clinical characteristics. We found that comutations of both STK11 and KEAP1 are strong determinants of unfavorable prognosis with currently available therapies. In patients with targetable oncogenes (eg, EGFR, ALK, ROS1) who received targeted therapies, the tumor genetic background additionally differentiated survival with mutations in TP53 and ARID1A, which contributed to a higher risk score for shorter survival. CONCLUSION A mutational profile derived from broad-panel sequencing presents an effective genomic stratification for patient survival in advanced lung adenocarcinoma. OncoCast is available as a public resource that facilitates the incorporation of mutational data to predict individual patient prognosis and compare risk characteristics of patient populations.
科研通智能强力驱动
Strongly Powered by AbleSci AI